Analyst consensus rating
Neumora Therapeutics, Inc. Analyst Rating: Buy
NMRA is rated Buy by 8 analysts with a $6.28 target. As of 2026-08-16.
Direct answer
Neumora Therapeutics, Inc.'s consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.28.
Forecast evidence checked August 16, 2026.
Get free Neumora Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.60
- Average price target
- $6.28
- High price target
- $14.00
- Low price target
- $3.00
- Low target gap
- +87.5%
- Target upside
- +292.7%
- High target gap
- +775%
- Target range width
- 687.5%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 16, 2026
- Valid through
- August 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neumora Therapeutics, Inc.?
Neumora Therapeutics, Inc. has a verified Buy consensus. The same dataset has an average price target of $6.28.
How far are Neumora Therapeutics, Inc.'s low and high targets from the recorded price?
The low target implies +87.5%, while the high target implies +775%.
How many analysts are included in Neumora Therapeutics, Inc.'s consensus?
The verified consensus includes 8 analysts.
How is Neumora Therapeutics, Inc.'s target upside or downside calculated?
The average target of $6.28 is divided by the recorded price of $1.60, then one is subtracted to produce +292.7%. This does not guarantee a future return.
When was Neumora Therapeutics, Inc.'s analyst forecast verified?
The data was verified on 2026-08-16. The dataset is valid through 2026-08-23.